Decode
Reykjavik, IS · 1 known investors
deCODE analyzes and interprets the human genome to identify genetic risk factors for common diseases including cardiovascular disease and cancer. The company serves pharmaceutical and research organizations through genomic discovery and analysis.
Also known as ADG · Amgen deCODE genetics · deCODE genetics
Investors · 1
Company profile
researched Aug 2026deCODE genetics is a human genetics research company headquartered in Reykjavik, Iceland, and founded in 1996. It analyzes and interprets the human genome, using population-scale resources and analytical expertise to identify genetic variations associated with human disease. The company states it has discovered key genetic risk factors for dozens of common diseases, ranging from cardiovascular disease to cancer.
The company operates as a subsidiary of Amgen and is referred to in its own communications as Amgen deCODE genetics (ADG). Its output is largely scientific: it publishes discoveries in peer-reviewed journals so that others can validate and extend the findings. Recent reported work includes the construction of what the company describes as the first Icelandic pangenome, built with a method that identifies 6% more genetic variants than previous approaches and that surfaced a previously undetected variant associated with a substantially increased disease risk, as well as contribution of Icelandic research data to an international fibromyalgia genetics study published in Nature Medicine in 2026.
Founding story
Sources state only that deCODE genetics was founded in 1996; no details on founders or founding circumstances are provided.
Business model
deCODE operates as a subsidiary of the biotechnology company Amgen, conducting human genetics research and gene discovery rather than functioning as an independent standalone venture. Sources do not describe pricing, contracts, or commercial terms.
Not described in the available sources.
Traction
Traction indicators available in the sources are scientific rather than commercial: a continuing stream of published discoveries in peer-reviewed journals, the first Icelandic pangenome, and participation in an international fibromyalgia genetics study published in Nature Medicine.
Latest developments
In 2026 the company reported the construction of the first Icelandic pangenome (August 2026), a new method identifying 6% more genetic variants than previous methods and revealing a previously undetected variant linked to substantially increased disease risk; contribution of Icelandic research data to a landmark fibromyalgia genetics study published in Nature Medicine (July 2026); the appointment of Daníel F. Guðbjartsson as Associate Vice President and Site Head (May 2026); and a visit to the Reykjavik facilities by Amgen CEO Bob Bradway (March 2026).
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company presents itself as a global leader in analyzing and understanding the human genome and claims to operate the most productive human gene discovery engine in the world. No third-party market share, ranking, or comparative data appears in the sources.
The company attributes its position to a combination of proprietary analytical expertise and Icelandic population resources, which it says allow large-scale gene discovery; it describes itself as operating the most productive human gene discovery engine in the world. These are company self-descriptions.
Technology
The company applies genome analysis and gene discovery methods to population-scale human genetic data to identify variants associated with disease. A recently described method used to build the Icelandic pangenome identifies 6% more genetic variants than previous methods.
Go-to-market
Publication of discoveries in major peer-reviewed journals is the primary externally visible channel described in the sources; no sales or marketing motion is described.
Not specified in the available sources beyond the scientific and research community that uses its published findings.
Geography
Headquartered in Reykjavik, Iceland, with research drawing on Icelandic population data; the company describes itself as a global leader in human genetics and participates in international research collaborations.
History
The company states it was founded in 1996 and is headquartered in Reykjavik, Iceland. It is described on its own site as a subsidiary of the global biotechnology company Amgen and is also referred to as Amgen deCODE genetics (ADG). In March 2026, Amgen CEO Bob Bradway visited the Reykjavik facilities, and in May 2026 the company announced the appointment of Daníel F. Guðbjartsson, Ph.D. as Associate Vice President and Site Head, responsible for leading site operations.
Risks & controversies
No risks or controversies are described in the available sources.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlap
Companies competing with Decode for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 4
launches, deals, and filingsScientists at Amgen deCODE genetics constructed the first Icelandic pangenome using a new method that identifies 6% more genetic variants than previous methods and revealed a previously undetected variant associated with substantially increased disease risk.
An international team of researchers, drawing on Icelandic research data, identified new genetic risk factors associated with fibromyalgia in a study published in Nature Medicine.
deCODE genetics announced the appointment of Daníel F. Guðbjartsson, Ph.D. as Associate Vice President and Site Head, leading site operations for the company.
Bob Bradway, CEO of Amgen, visited the facilities of Amgen deCODE genetics in Reykjavik on March 11, learning about operations and meeting executives.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Decodedecode.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Decode do?
- Reykjavik-based human genetics company, an Amgen subsidiary founded in 1996, discovering genetic risk factors for common diseases.
- Who are Decode's investors?
- Decode's investors include ARCH Venture Partners.
- Where is Decode headquartered?
- Decode is headquartered in Reykjavik, IS.